Evidence and regulatory context for peptide-based treatments connected to metabolic health.
Established / approved options
Semaglutide, tirzepatide, liraglutide, and glucagon have product-specific roles relevant to metabolic health or severe hypoglycemia.
Being researched
MOTS-C is being researched, but FDA approval and adequate human safety evidence are lacking.
How to use this page
Established options appear before experimental compounds. Goal relevance never overrides regulatory status or evidence quality.
Next step
Open the relevant treatment review for sources, risks, contraindications, and evidence gaps.
MyPeptideQuest
Information only. Not medical advice. No dosing or self-treatment instructions are provided.